1 **running title: An application for aiding COVID-19 diagnosis**

2 **Development and utilization of an intelligent application for aiding COVID-19**

3 **diagnosis**

4 Zirui Meng^{1,a}, Minjin Wang^{1,a}, Huan Song^{2,a}, Shuo Guo¹, Yanbing Zhou¹, Weimin Li³,

5 Yongzhao Zhou³, Mengjiao Li¹, Xingbo Song¹, Yi Zhou¹, Qingfeng Li⁴, Xiaojun Lu¹,

6 Binwu Ying^{1,*}

7 ¹ *Department of Laboratory Medicine, West China Hospital, Sichuan University,*

8 *Chengdu, Sichuan Province, China*

9 ² *West China Biomedical Big Data Center, West China Hospital, Sichuan University,*

10 *Chengdu, Sichuan Province, China*

11 ³ *Department of Respiratory and critical care medicine, West China Hospital, Sichuan*

12 *University, Chengdu, Sichuan Province, China*

13 ⁴ *Department of Clinical Laboratory, Public Health Clinical Center of Chengdu,*

14 *Chengdu, Sichuan Province, China.*

15 ^a*Zirui Meng, Minjin Wang, Huan Song. contributed equally to this work.*

16 *Correspondence author: Binwu Ying. No.37 Guoxue Alley, West China Hospital,*

17 *Sichuan University, Chengdu 610041, Sichuan Province, P. R China.*

18 *Tel:86-028-85422751*

19 *Fax:86-028-85422751*

20 *Email:binwuying@126.com*

21

22

23 **Development and utilization of an intelligent application for aiding COVID-19**

24 **diagnosis**

25 **ABSTRACT**

26 **Background:** COVID-19 has been spreading globally since emergence, but the
27 diagnostic resources are relatively insufficient.

28 **Results:** In order to effectively relieve the resource deficiency of diagnosing
29 COVID-19, we developed a machine learning-based diagnosis model on basis of
30 laboratory examinations indicators from a total of 620 samples, and subsequently
31 implemented it as a *COVID-19 diagnosis aid APP* to facilitate promotion.

32 **Conclusions:** External validation showed satisfiable model prediction performance
33 (i.e., the positive predictive value and negative predictive value was 86.35% and
34 84.62%, respectively), which guarantees the promising use of this tool for extensive
35 screening.

36 **Keywords:** Corona Virus Disease 2019; diagnostic; machine learning; laboratory
37 testing; Application.

38

39 **BACKGROUND**

40 Since the outbreak of Corona Virus Disease 2019(COVID-19) in Wuhan, in December
41 2019, the epidemic has spread rapidly all over the world, which consequently brought
42 great challenges to global public health(1). As of March 14, a total of 142,539 cases
43 had been confirmed worldwide, with many more requiring tests(2). Currently,
44 accurate nucleic acid detection plays a pivotal role in diagnosis and prevention of

45 COVID-19, and reverse transcription polymerase chain reaction is the main method
46 for nucleic acid detection(3). However, it is not feasible to use this time-and
47 labor-consuming approach for screening a large growing number of suspected patients
48 and asymptomatic infected patients(4). Rapid and universal screening method is
49 essential to save medical resources, improve diagnosis efficiency and avoid
50 cross-infection.

51 Taking advantage of the emerging machine learning technique, which enables analysis
52 of the existing multidimensional data by applying appropriate algorithms for feature
53 expression and classification, we have potential to improve the accuracy of diagnosis.
54 For instance, in a recent study published in Nature, deep learning-based statistical
55 model was used to improve breast cancer treatment and survival through identifying
56 breast cancer patients with a high risk of long-term recurrence(5). In this study, we
57 analyzed a variety of basic laboratory examinations indicators that related to host
58 reactions to generate a free COVID-19 diagnosis aid APP. Then, the accuracy of this
59 app was validated in an independent cohort(6).

60 **METHODS**

61 **Patients and information collection**

62 We have complied with all relevant ethical regulations for work with human subjects
63 and the studies were approved by the Clinical Trials and Biomedical Ethics
64 Committee of West China Hospital, Sichuan University. Through the West China
65 hospital, a regional medical center, we collected the information of confirmed
66 COVID-19 cases from various regional medical institutions, between 20th December

2019 and 10th February 2020. Diagnostic criteria were: RT-PCR of respiratory or blood samples was positive for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) nucleic acid; or viral gene sequencing of respiratory or blood sample was highly homologous with SARS-CoV-2. Controls were patients collected in the same site and the same time period, who were free of COVID-19 but had a diagnosis of viral pneumonia. Results of laboratory examinations on admission were collected which included age, gender and 35 indicators of whole blood count, coagulation test and biochemical examination. In addition, the independent validation cohort consisted of samples collected prospectively from one single medical center, using similar data collection strategy.

Feature selection and model construction

Factors under consideration are age, sex and indicators of basic laboratory examinations(see Table 1). Using 70% samples from the derivation cohort (i.e., the training set), we first performed feature selection using Least Absolute Shrinkage and Selection Operator (LASSO) to select the valuable indicators of COVID-19. The main idea of LASSO for feature selection is to construct a first-order penalty function, which can shrink the regression coefficient (b) of each variable within a certain range, and eliminate the feature with a coefficient of 0, and finally obtain an optimally refined model(7). The penalty terms for LASSO are: $\sum (abs(b)) \leq t$. Then these indicators were used to construct a primitive model by multivariate logistic regression. The parameters were further adjusted through internal validation (i.e., the other 30% samples, the testing set) to obtain the optimized final model.

89 **Evaluation**

90 In external validation cohort, we compared the predicted results, with the follow-up
91 results to evaluate the diagnostic validity by positive predictive values, and negative
92 predictive values. Finally, to facilitate further use in clinic setting, all model
93 parameters and code were encapsulated as a visual application(APP), *COVID-19*
94 *Diagnosis Aid APP*.

95 **Statistical analysis**

96 Continuous variables are represented by the median (upper and lower quartiles).
97 Categorical variables are expressed in terms of frequency. LASSO algorithm was used
98 for feature selection and the model was constructed by multivariate logistic regression.
99 The diagnostic performance of the model was assessed by AUC. Calibration curves
100 and Hosmer-Lemeshow test were used to evaluate the degree of overestimation or
101 underestimation of the model. DCA were used to measure the net clinical benefits.
102 The LASSO algorithm was performed by “glmnet” package. The logistic regression
103 model was constructed by “glm” package. All statistical analyses were completed
104 using R 3.5.0 version.

105 **RESULTS**

106 **Participants and Clinical Characteristics**

107 A total of 620 samples were included in the derivation cohort, among which 431
108 samples (211 COVID-19 vs. 220 Control) were in the training set and 189 samples
109 (91 COVID-19 vs. 98 Control) were in testing set by simple randomization. The
110 frequency of COVID-19 in the training set (48.96%) was not significantly different

111 from that in the testing set (48.14%). We included 145 samples in the independent
112 validation cohort.

113 **Model development and evaluation**

114 Through Lasso regression screening and Multivariate logistic regression, 9
115 representative variables (age, Activated Partial Thromboplastin Time, Red Blood Cell
116 Distribution Width-SD, Uric Acid, Triglyceride, Serum Potassium, Albumin/globulin,
117 3-Hydroxybutyrate, Serum Calcium) with good identification value were selected and
118 constructed an optimized diagnostic model(see Figure 1). According to the suggestive
119 information from the model, among 145 samples that used for validation, 80 samples
120 were estimated as COVID-19 and 65 samples were considered COVID-19-free.
121 Compared with the status determined by nucleic acid detection (the golden standard),
122 we found 69 real COVID-19 samples were correctly identified by the app (69/80,
123 positive predictive value =86.25%), while 55, out of the 65 COVID-19-free samples,
124 were confirmed to be negative (55/65, negative predictive value =84.62%). The area
125 under curve (AUC) of the model were 0.890 and 0.872 in the testing set and
126 independent validation cohort, respectively(see Figure 2)(8). The calibration curve
127 performed well and Hosmer-Lemeshow test results P value was much greater than
128 0.05(see Figure 3). The DCA quantitatively demonstrated high clinical net benefit
129 over the entire probability threshold(see Figure 4)(9).

130 **Construction of application**

131 The model was encapsulated as an APP, *COVID-19 Diagnosis Aid APP*. The risk of
132 COVID-19 can be obtained by inputting the required indicators into the APP. It will

133 be online in the android store and IOS APP Store soon for facilitating the further
134 application(see Figure 5).

135 **DISCUSSION**

136 According to the latest epidemiological information of the World Health
137 Organization(WHO), SARS-CoV-2 is spreading worldwide with an intensifying
138 situation, and many countries including South Korea, Italy, and the United States have
139 experienced outbreaks(10). Timely diagnosis, isolation and treatment are critical to
140 control the global spread of COVID-19. However, nucleic acid testing is not always
141 feasible or fully affordable in all regions. We therefore need more ways to realize the
142 early and accurate community control and screening of suspicious people. To our
143 knowledge, this is the first COVID-19 Diagnosis Aid APP based on laboratory tests
144 for extensive screening. It has good accuracy and stability, which can help medical
145 institutions to predict patients' situation in advance and accurately invest the limited
146 healthcare resources, so as to effectively control the spread of the epidemic.

147 Based on the optimized diagnostic model developed in current study, users can obtain
148 the probability of COVID-19 according to the simple, easily available and reliable
149 indicators from laboratory examinations. Given satisfiable model prediction
150 performance (i.e., AUC was 0.872; positive predictive value and negative predictive
151 value was reach 86.25% and 84.62%, respectively in independent validation cohort),
152 the application of this app can provide reliable suggestion for further assessment of
153 the index person, which has potential to reduce anxiety of public, as well as
154 unnecessary hospital visit and nucleic acid testing.

155 It is undeniable that nucleic acid detection is one of the most reliable standards for the
156 diagnosis of COVID-19, but we should also be aware of its shortcomings and
157 deficiencies in practice. Nucleic acid testing requires professional technical platforms
158 and physicians, and false negative results due to multiple reasons cannot be
159 completely avoided(11). Instead, laboratory indicators that identified in our study are
160 accessible, and can be widely used in community hospitals by family doctors to
161 complete the early stage of suspected population screening.

162 On the other hand, based on the technological revolution brought by the Internet, this
163 APP software installed on personal mobile can not only help to discover COVID-19
164 in the most convenient way, but also timely monitor dynamic trends of the prevalence
165 of the contagious disease through data transmission to the Disease Control Center or
166 professional medical institution(12, 13). This provides real-time data with predictive
167 value, which can be reliable basis for more accurate health and epidemic prevention
168 policies. Furthermore, this APP software is continuously upgradeable, with the
169 possibility of extended scope of application. For example, we have added the
170 data acquisition function which enabled the documentation of epidemiological and
171 clinical features and a personalized reminder for necessary revisits. Also, with further
172 implementation of communication function, it is possible to establish a direct
173 pre-connection between individuals and medical centers, which may benefit patients
174 by avoiding unnecessary hospital visits or shorten waiting time spend before
175 admission (14).

176 **CONCLUSION**

177 *COVID-19 Diagnosis Aid APP* can efficiently and accurately calculate the infection
178 probability through simple and easily-obtained laboratory examination results. It will
179 promote the screening of a large number of suspected people, save limited medical
180 resources, optimize the diagnosis process, and it can constantly learn, adapt and
181 upgrade, which are vital to control the global spread of COVID-19.

182

183 **Ethics approval and consent to participate**

184 The protocol of this study was approved by the West China Hospital, Sichuan
185 University Medical Ethics Committee and conformed to the principles of the
186 Declaration of Helsinki.

187 **The registry number for clinical trial**

188 ChiCTR2000030542

189 **Consent for publication**

190 Not applicable

191 **Data Availability Statement**

192 The datasets used and analysed during the current study are available from the
193 corresponding author on reasonable request.

194 **Competing interests**

195 The authors declare that they have no competing interests

196 **Funding**

197 This study was supported by Science and Technology Department of Sichuan
198 Province “2020YFS0004” and Science and Technology Project of West China

199 Hospital “HX-2019-nCov-066”

200 **Authors' contributions**

201 Zirui Meng analyzed the data and was a major contributor in writing the manuscript.

202 Minjin Wang designed the APP framework and was a major contributor in writing the

203 manuscript. Huan Song analyzed the data and was a major contributor in writing the

204 manuscript. Shuo Guo analyzed the data. Yanbing Zhou analyzed the data. Weimin Li

205 analyzed patients' medical records. Yongzhao Zhou analyzed patients' medical records.

206 Mengjiao Li collected the data. Xingbo Song verified the performance of the app. Yi

207 Zhou verified the performance of the app. Qingfeng Li collected the data. Xiaojun Lu

208 designed the functions of the app. Binwu Ying proposed research ideas and design

209 research programs. All authors read and approved the final manuscript.

210 **Acknowledgements**

211 The authors thank Beijing Zhongben Tech.co.,Ltd. for their technical contributions to

212 this study.

213 **REFERENCE**

214 1. Z W, JM M. Characteristics of and Important Lessons From the Coronavirus

215 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72□314

216 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020.

217 2. Data as reported by national authorities by 10 AM CET 14 March 2020

218 [Available from:

219 <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200314-sit>

220 [ep-54-covid-19.pdf?sfvrsn=dcd46351_6](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200314-sit-ep-54-covid-19.pdf?sfvrsn=dcd46351_6).

- 221 3. VM C, O L, M K, R M, A M, DKW C, et al. Detection of 2019 novel coronavirus
222 (2019-nCoV) by real-time RT-PCR. Euro surveillance : bulletin Europeen sur les
223 maladies transmissibles = European communicable disease bulletin. 2020;25(3).
- 224 4. T K, SM J, NM L, R K, K H, T M, et al. Communicating the Risk of Death from
225 Novel Coronavirus Disease (COVID-19). Journal of clinical medicine. 2020;9(2).
- 226 5. OM R, SJ S, JA S, SF C, JL C-J, M C, et al. Dynamics of breast-cancer relapse
227 reveal late-recurring ER-positive genomic subgroups. Nature.
228 2019;567(7748):399-404.
- 229 6. F S, N S, F S, Z Z, J S, H L, et al. Emerging Coronavirus 2019-nCoV Pneumonia.
230 Radiology. 2020:200274.
- 231 7. Tibshirani R. The lasso method for variable selection in the cox model. Stat Med.
232 1997;16(4):385-95.
- 233 8. Muntner P, Colantonio LD, Cushman M, Goff DC, Jr., Howard G, Howard VJ, et
234 al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk
235 equations. JAMA. 2014;311(14):1406-15.
- 236 9. Vickers AJ, Elkin EB. Decision curve analysis: A novel method for evaluating
237 prediction models. Med Decis Making. 2006;26(6):565-74.
- 238 10. S BS, P R, Y S, A M, C C, A S, et al. First cases of coronavirus disease 2019
239 (COVID-19) in France: surveillance, investigations and control measures, January
240 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles =
241 European communicable disease bulletin. 2020;25(6).
- 242 11. T A, Z Y, H H, C Z, C C, W L, et al. Correlation of Chest CT and RT-PCR Testing

- 243 in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.
- 244 Radiology. 2020:200642.
- 245 12. CS W, MR T, J B, TP M-T, K H, D P, et al. Taking connected mobile-health
- 246 diagnostics of infectious diseases to the field. Nature. 2019;566(7745):467-74.
- 247 13. EV G, A S, ND C. Using the Internet to identify infectious-disease outbreaks. The
- 248 New England journal of medicine. 2004;351(24):2558-9.
- 249 14. JT W, K L, GM L. Nowcasting and forecasting the potential domestic and
- 250 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a
- 251 modelling study. Lancet (London, England). 2020.

265 **Table 1. Candidate of the model.**

	Derivation cohort		Validation cohort	
	Control	COVID-19	Control	COVID-19
SEX	female(27.41%)	female(31.07%)	female(31.21%)	female(30.56%)
AGE	68.5(77,81)	46(55,73)	66(76,84)	48(58,67)
PT	11(11.75,13.25)	10.7(11.8 ,13.4)	11.1(12,13.7)	11(11.7,12.7)
INR	0.95(1.06,1.15)	0.94(1.04,1.16)	0.97(1.06,1.20)	0.96(1.02,1.12)
APTT	28.18(29.75,35.68)	25.60(27.90,31.40)	27.38(30.10,35.43)	25.68(28.25,32.20)
TT	17.10(18.00,19.13)	16.40(17.20,18.10)	17.20(18.20,19.60)	16.98(17.90,19.10)
RBC	3.13(3.76,4.13)	3.66(4.25,4.76)	3.10(3.68,4.15)	3.47(3.98,4.44)
HGB	93.25(110.50,126.50)	111.00(129.00,148.00)	91.75(110.00,123.00)	103.00(119.00,135.00)
HCT	0.29(0.35,0.39)	0.35(0.38,0.44)	0.29(0.34,0.38)	0.32(0.36,0.40)
MCV	88.13(92.20,96.30)	88.50(91.50,95.00)	88.90(93.25,97.20)	88.40(91.65,95.53)
MCH	29.00(29.90,31.20)	28.90(30.70,32.10)	28.90(30.00,31.30)	29.10(0.40,31.70)
MCHC	317.00(325.00,335.25)	320.00(334.00,345.00)	314.00(324.00,332.00)	318.00(328.00,339.00)
RDW-SD	44.58(47.45,51.13)	41.90(44.50,49.80)	45.08(49.20,54.10)	42.65(46.20,50.25)
RDW-CV	13.40(14.10,15.33)	12.80(13.60,15.10)	13.70(14.60,15.90)	13.18(13.90,14.90)
PLT	135.75(186.00,230.75)	107.00(147.00,202.00)	130.00(203.50,276.25)	126.75(203.50,277.75)
WBC	5.73(7.39,9.02)	6.52(9.59,14.89)	5.87(8.02,11.04)	5.22(7.42,11.09)
TBIL	6.20(9.75,15.18)	8.50(12.20,17.50)	6.90(9.65,14.48)	7.60(10.30,14.40)
DBIL	2.48(3.80,6.28)	3.70(5.70,7.50)	2.90(4.40,7.13)	3.30(4.60,7.23)

IBIL	3.78(4.95,6.98)	4.00(6.10,9.10)	3.30(4.60,7.10)	3.40(5.10,7.50)
ALT	12.00(19.00,30.25)	18.00(27.00,55.00)	13.00(21.00,37.00)	19.00(31.50,57.00)
AST	18.75(23.00, 36.00)	22.00(36.00,68.00)	19.00(25.50,39.25)	21.00(33.00,55.00)
TP	53.90(58.85,68.13)	60.80(65.90,72.10)	56.48(62.05,68.53)	55.90(60.85,66.33)
ALB	32.70(36.10,41.65)	30.70 (34.10,39.00)	31.30(34.75,38.53)	29.90(32.95,37.23)
GLB	19.43(23.80,28.45)	27.50(31.80,35.90)	22.50(26.50,30.93)	23.38(27.00,31.60)
A/G	1.33(1.51,1.91)	0.90(1.11,1.32)	1.11(1.35,1.61)	1.03(1.22,1.46)
GLU	4.92(6.00,7.64)	6.31(7.33,9.67)	5.49(7.20,9.40)	5.10(6.24,8.40)
UREA	4.60(6.05,8.25)	4.20(6.20,10.40)	4.58(6.69,9.43)	3.40(4.73,7.00)
CREA	50.50(60.50,103.50)	60.00(75.00,94.00)	50.00(65.50,90.00)	51.00(61.00,77.00)
eGFR	60.87(89.49,97.73)	66.14(96.38,104.66)	63.45(86.14,100.87)	87.21(101.88,112.20)
Cys-C	0.90(1.06,1.69)	0.86(1.06,1.42)	0.92(1.16,1.68)	0.82(0.96,1.23)
URIC	154.75(219.00,291.25)	181.00(281.00,366.00)	133.75(200.00,287.25)	138.00(192.00,281.00)
TG	0.71(0.93,1.23)	0.98(1.17,1.80)	0.76(1.03,1.34)	0.94(1.30,1.82)
CK	41.75(56.00,86.75)	39.00(87.00,204.00)	29.00(49.50,84.25)	36.00(62.00,125.25)
NA	135.30(139.20,141.83)	131.40(135.50,139.10)	135.95(139.70,142.60)	135.80(139.15,141.70)
K	3.72(4.08,4.38)	3.32(3.76,4.09)	3.73(4.08,4.51)	3.57(3.96,4.38)
β-HBA	0.07(0.12,0.23)	0.08(0.23,0.38)	0.07(0.11,0.22)	0.06(0.12,0.30)
CA	2.06(2.15,2.21)	2.01(2.11,2.23)	2.02(2.14,2.24)	1.97(2.07,2.17)

266 Data are presented as n (%) for categorical variables and as median (interquartile range) for continuous variables.

267 PT, prothrombin time; INR, International Normalized Ratio; APTT, activated partial thromboplastin time; TT,

268 thromboplastin time; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, Mean Corpuscular Volume;

269 MCH, Mean Corpuscular Hemoglobin; MCHC, Mean Corpuscular Hemoglobin Concentration; RDW-SD, Red
270 Blood Cell Distribution Width-SD; RDW-CV, Red Blood Cell Distribution Width-CV; PLT, Platelets; WBC, white
271 blood cell; TBIL, total Bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; ALT, alanine aminotransferase;
272 AST, glutamic oxaloacetic transaminase; TP, Total Protein; Alb, albumin; ALB, albumin; GLB, globulin ratio; A/G,
273 albumin globulin ratio; GLU, glucose; CREA, serum; eGFR, estimated Glomerular Filtration Rate; Cys-C, cystatin;
274 URIC, uric acid; TG, Triglyceride; CHOL, cholesterol; CK, creatine kinase; NA, serum sodium; K, Serum
275 Potassium; β -HBA, 3-Hydroxybutyrate; CA, Serum Calcium;

276

277 **Figure legends**

278 **Figure.1(a) Coefficient diagram of LASSO variables.** Each curve in the figure
279 represents the trajectory of the coefficient of an independent variable. The ordinate is
280 the value of the coefficient. The lower abscissa, λ , is the parameter that controls the
281 severity of the penalty. The upper abscissa is the number of non-zero coefficients in
282 the model under the penalty parameter. **(b) Adjustment parameters in the LASSO**
283 **model.** The lambda is screened by 10 folds cross-validation. A dashed vertical line is
284 drawn at one standard error (1-SE standard) of the minimum and minimum standards.
285 Lambda.1se corresponds to a model with good performance but the fewest number of
286 arguments.

287 **Figure 2. Receiver operator characteristic curve.** The AUC were 0.890 and 0.872
288 in derivation and validation cohort respectively.

289 **Figure 3. Calibration curves.** The 45° shaded line represents the ideal prediction and
290 the prediction probability is consistent with the actual observation probability. The

291 Solid line represents the actual prediction of the model. The stapled histogram on the
 292 bottom line represents the distribution of patients' predicted probability. Abbreviations:
 293 Dxy = Somer's D rank correlation, R² = Nagelkerke-Cox-Snell-Maddala- Magee
 294 R-squared index, D = Discrimination index, U = Unreliability index, Q = Quality
 295 index, Emax = maximum absolute difference in predicted and calibrated propabilities,
 296 S:z = Spiegelhalter Z-Test, S:p = two-tailed p-value of the Spiegelhalter Z-test.

297 **Figure 4. Decision curve analysis.** The horizontal axis is the threshold probability of
 298 occurrence of COVID-19. The vertical axis shows the clinical benefits that patients
 299 may gain or lose using the APP. Dotted line: prediction model. Solid line: all patients
 300 were COVID-19 . Horizontal line: all patients were not COVID-19.

301 **Figure 5. APP schematic.** The model can show the probability of COVID-19 after
 302 inputing the corresponding index into the the APP.

a

b

Actual Probability

09:34 MZR

West China Hospital COVID-19 Screening Assistant

Fill in each assay index in detail, get probability after submitting

[Modify clinical symptoms](#)

Please fill in the data source of this laboratory test

Check the hospital Please enter hospital name

Check date Please select the inspection date >

Contact Way Please enter contact way

[Fill in all test indicators](#)

09:36

West China Hospital COVID-19 Screening

- [Personal data](#)
- [My case](#)
- [Feedback](#)
- [Contact us](#)
- [Setting](#)

09:34

[Fill in all test indicators](#) [Submit](#)

Check the hospital Please enter hospital name

Check date Please select the inspection date >

Contact Way Please enter contact way

Gender Please select gender >

age(AGE) Please enter age

Red Blood Cell Distribution Width-SD(RDW-SD) Please enter the value FL

Activated Partial Thromboplastin Time(APTT) Please enter the value S

Triglyceride(TG) Please enter the value mmol/L

Albumin/globulin(A/G) Please enter the value

Uric Acid(URIC) Please enter the value umol/L

Serum Potassium(K) Please enter the value mmol/L

Serum Calcium(CA) Please enter the value mmol/L

09:36

Diagnostic probability

Probability value

86.20%

According to your test results, you are at higher risk of COVID-19. Do not be panic. Please observe your physical condition closely. It is recommended to wear a mask and consult a local doctor.

[Back Homepage](#)

If you have any questions, please send them to the following mailbox
Huaxi_Coronavirus@126.com

09:36

My case

2020-03-18 09:36:01 [Probability value:86.2%](#)

Check the hospital westChina

Check date 2020-03-18

Contact Way 15780917878

Gender 女

Age 23 [View details](#)

2020-03-17 15:29:58 [Probability value:94.15%](#)

Check the hospital WestChina

Check date 2020-03-07

Contact Way 15680916878

Gender 女

Age 23 [View details](#)

2020-03-17 11:17:36 [Probability value:99.71%](#)

Check the hospital West China

Check date 2020-03-12

Contact Way 15680916878

Gender 女